|
|||||
|
|
An updated cost-effectiveness analysis of evolocumab therapy for reducing cardiovascular events in very high-risk patients with atherosclerotic cardiovascular disease according to the 2018 ACC/AHA guideline |
|
| Authors: | Gregg C. Fonarow Ben van Hout Guillermo Villa Jorge Arellano Peter Lindgren |
| Affiliation: | Los Angeles, CA |
| Abstract: | |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ | |